158 related articles for article (PubMed ID: 11144793)
1. MRI with mangafodipir trisodium in the detection of pancreatic tumours: comparison with helical CT.
Rieber A; Tomczak R; Nüssle K; Klaus H; Brambs HJ
Br J Radiol; 2000 Nov; 73(875):1165-9. PubMed ID: 11144793
[TBL] [Abstract][Full Text] [Related]
2. MRI with mangafodipir trisodium in the detection and staging of pancreatic cancer.
Romijn MG; Stoker J; van Eijck CH; van Muiswinkel JM; Torres CG; Laméris JS
J Magn Reson Imaging; 2000 Aug; 12(2):261-8. PubMed ID: 10931589
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance with manganese-DPDP (mangafodipir) of focal solid pancreatic lesions.
Zanello A; Nicoletti R; Brambilla P; Boccuni R; Di Carlo V; Staudacher C; Del Maschio A
Radiol Med; 2004 Sep; 108(3):194-207. PubMed ID: 15343134
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT.
Schima W; Függer R; Schober E; Oettl C; Wamser P; Grabenwöger F; Ryan JM; Novacek G
AJR Am J Roentgenol; 2002 Sep; 179(3):717-24. PubMed ID: 12185052
[TBL] [Abstract][Full Text] [Related]
5. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
6. MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents.
Youk JH; Lee JM; Kim CS
AJR Am J Roentgenol; 2004 Oct; 183(4):1049-54. PubMed ID: 15385303
[TBL] [Abstract][Full Text] [Related]
7. Secretin-stimulated multi-detector CT versus mangafodipir trisodium-enhanced MR imaging plus MRCP in characterization of non-metastatic solid pancreatic lesions.
Boraschi P; Donati F; Gigoni R; Salemi S; Faggioni L; Del Chiaro M; Boggi U; Bartolozzi C; Falaschi F
Dig Liver Dis; 2009 Nov; 41(11):829-37. PubMed ID: 19303825
[TBL] [Abstract][Full Text] [Related]
8. [MR imaging of pancreatic lesions with Mn-DPDP. A histopathologic correlation].
Dobritz M; Fellner FA; Baum U; Nömayr A; Lell M; Klein P; Papadopoulos T; Bautz W
Rofo; 2002 Jul; 174(7):893-7. PubMed ID: 12101481
[TBL] [Abstract][Full Text] [Related]
9. Mangafodipir trisodium-enhanced MR imaging of pancreatic disease.
Boraschi P; Donati F; Gigoni R; Caramella D; Boggi U; Falaschi F; Bartolozzi C
Eur Radiol; 2006 May; 16(5):988-97. PubMed ID: 16421713
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of portal-phase CT and MRI with mangafodipir trisodium in detecting liver metastases from colorectal carcinoma.
Regge D; Campanella D; Anselmetti GC; Cirillo S; Gallo TM; Muratore A; Capussotti L; Galatola G; Floriani I; Aglietta M
Clin Radiol; 2006 Apr; 61(4):338-47. PubMed ID: 16546464
[TBL] [Abstract][Full Text] [Related]
11. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET.
Sahani DV; Kalva SP; Fischman AJ; Kadavigere R; Blake M; Hahn PF; Saini S
AJR Am J Roentgenol; 2005 Jul; 185(1):239-46. PubMed ID: 15972430
[TBL] [Abstract][Full Text] [Related]
12. Mangafodipir-DPDP enhanced MRI visualization of a pancreatic adenocarcinoma previously undetected by extracellular contrast enhanced CT and MRI.
De Filippo M; Bocchi C; Quartieri L; Corradi D; Zompatori M
Acta Biomed; 2007 Dec; 78(3):225-8. PubMed ID: 18330084
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic enhancement and pulse sequence analysis using low-dose mangafodipir trisodium.
Mayo-Smith WW; Schima W; Saini S; Slater GJ; McFarland EG
AJR Am J Roentgenol; 1998 Mar; 170(3):649-52. PubMed ID: 9490946
[TBL] [Abstract][Full Text] [Related]
14. Influence of the hepatobiliary contrast agent mangafodipir trisodium (MN-DPDP) on the imaging properties of abdominal organs.
Jung G; Heindel W; Krahe T; Kugel H; Walter C; Fischbach R; Klaus H; Lackner K
Magn Reson Imaging; 1998 Oct; 16(8):925-31. PubMed ID: 9814775
[TBL] [Abstract][Full Text] [Related]
15. Identification and staging of pancreatic tumours using computed tomography, endoscopic ultrasound and mangafodipir trisodium-enhanced magnetic resonance imaging.
Ramsay D; Marshall M; Song S; Zimmerman M; Edmunds S; Yusoff I; Cullingford G; Fletcher D; Mendelson R
Australas Radiol; 2004 Jun; 48(2):154-61. PubMed ID: 15230749
[TBL] [Abstract][Full Text] [Related]
16. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
Chung JJ; Kim MJ; Kim KW
J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
[TBL] [Abstract][Full Text] [Related]
17. [The clinical value of Mn-DPDP: a new paramagnetic hepatobiliary contrast medium for magnetic resonance tomography of the liver].
Vogl TJ; Hamm B; Schnell B; Eibl-Eibesfeldt B; Steiner S; Lissner J
Rofo; 1991 Dec; 155(6):568-74. PubMed ID: 1764599
[TBL] [Abstract][Full Text] [Related]
18. Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT.
Oudkerk M; Torres CG; Song B; König M; Grimm J; Fernandez-Cuadrado J; Op de Beeck B; Marquardt M; van Dijk P; de Groot JC
Radiology; 2002 May; 223(2):517-24. PubMed ID: 11997562
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP).
Murakami T; Baron RL; Peterson MS; Oliver JH; Davis PL; Confer SR; Federle MP
Radiology; 1996 Jul; 200(1):69-77. PubMed ID: 8657947
[TBL] [Abstract][Full Text] [Related]
20. Small (Kim KW; Kim AY; Kim TK; Park SH; Kim HJ; Lee YK; Park MS; Ha HK; Kim PN; Kim JC; Lee MG
AJR Am J Roentgenol; 2004 May; 182(5):1233-40. PubMed ID: 15100125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]